WellGen, Inc.
WellGen, Inc. (“WellGen”) applies proprietary nutrigenomics technology to the discovery of food and dietary supplement ingredients from plants and foods for the health and wellness markets. WellGen is a spin-out of Rutgers University and has an exclusive worldwide license to a proprietary platform technology, which screens food and plant extracts for their impact on gene expression associated with a range of health states from the proliferation of cancer to exercise performance. The company’s business focus is to bring innovation to the US $84 billion functional foods and beverage markets. WellGen provides global brands with meaningful and understandable claims with the scientific support to stand up to regulatory scrutiny. While the focus is the food and beverage industry, opportunistic partnerships may be developed in pet products, cosmetics, OTC drugs, and pharmaceuticals.
Amphion’s fully-diluted ownership stake in WellGen was 15.01% as of 31 December 2007, valued at US $6.8 million (2006: US $4.9 million).
Management
Kathleen P. Mullinix, Ph.D. – President and Chief Executive Officer
Nancy Rawson, Ph.D. – Chief Scientific Officer
Patricia Lucas-Schnarre – Vice President of Product Development & Marketing
Catherine Segal, R.Ph – Vice President of Business Development
Board of Directors
Richard Laster, Chairman – Management Consultant, Former Chief Executive Officer, DNA Plant Technology Corp.
Robert J. Bertoldi – President and Chief Financial Officer, Amphion Innovations plc
Irwin Engelman – Former Chief Financial Officer, General Foods Corp.
Leif Kjargaard, Ph.D. – Senior Vice President, Danisco A/S
Scott Korman – President, Nashone, Inc.
Richard C.E. Morgan – Chief Executive Officer, Amphion Innovations plc
Kathleen P. Mullinix – President and Chief Executive Officer, WellGen Inc.
William R. Sharp, Ph.D. – Partner, GNP LLC
